Atraumatic convexal subarachnoid hemorrhage (cSAH) in elderly patients is a rare entity that has been associated with cerebral amyloid angiopathy (CAA) and intracerebral hematomas (ICH). To characterize this entity and to study these associations, 22 patients over 60 with cSAH were included in a multicenter ambispective cohort study. Clinical data, magnetic resonance imaging (MRI) studies, APOE genotyping, and cerebrospinal fluid (CSF) biomarkers were evaluated. Results were compared with data from healthy controls (HC), non-cSAH CAA patients (CAAo), and Alzheimer disease patients. Convexal subarachnoid hemorrhage presented with transient sensory or motor symptoms. At follow-up (median 30.7 months), 5 patients had died, 6 survivors showed functional disability (modified Rankins Scale (mRS)42), and 12 cognitive impairment. Four patients had prior ICH and six had an ICH during follow-up. CSF-Aß40 and Aß42 levels were lower in cSAH and CAAo compared with HC. Convexal subarachnoid hemorrhage presented an APOE-ε2 overrepresentation and CAAo had an APOE-ε4 overrepresentation. On MRI, all patients fulfilled CAA-modified Boston criteria and 9 showed cortical ischemia in the surrounding cortex or the vicinity of superficial siderosis. The neuropathologic study, available in one patient, showed severe CAA and advanced Alzheimer-type pathology. Convexal subarachnoid hemorrhage in the elderly is associated with cognitive impairment and lobar ICH occurrence. Our findings support the existence of an underlying CAA pathology.
INTRODUCTION
Atraumatic convexal subarachnoid hemorrhage (cSAH) is a rare type of cerebrovascular disease. Bleeding in cSAH is located in one or several adjacent sulci in the convexity of the brain. Two subtypes of cSAH have been proposed. The first subtype typically presents in young patients and has been associated with cerebral reversible vasoconstriction syndrome, while the second is usually observed in older patients and has been associated with cerebral amyloid angiopathy (CAA) and future lobar spontaneous intracerebral hemorrhage (ICH). 1, 2 The term CAA is used to describe the pathologic changes occurring in cortical and leptomeningeal cerebral vessels as the result of the deposition of β-amyloid proteins (Aß). The term ARIA (amyloid-related imaging abnormalities) refers to a spectrum of imaging abnormalities in the setting of amyloid-modifying therapeutic approaches. It includes signal changes thought to represent 'vasogenic edema', microhemorrhages, or cortical superficial siderosis (cSS). 3 The shift of amyloid in the perivascular spaces of small vessels is the common pathophysiologic mechanism underlying these phenomena. 3, 4 Vasogenic edema may occur rarely in the natural history of AD, and more commonly, in patients with presumed CAA. 3 The diagnostic criteria for CAA and ARIA rely on magnetic resonance imaging (MRI) findings. [3] [4] [5] Nonetheless, few recent studies have used other biomarkers. [6] [7] [8] [9] The APOE genotype is central in the pathogenesis of CAA and ICH, and also in Alzheimer's disease (AD). [10] [11] [12] [13] Convexal subarachnoid hemorrhage has been associated with lobar ICH in previous studies. 2, 14, 15 It has been proposed that the bleeding begins in the subarachnoid space in a subset of ICH. 16, 17 The rupture of arteries in the subarachnoid space would cause an initial bleeding contained by the surrounding cortex, which might develop ischemia. Subsequently, the hemorrhage would extend to the brain parenchyma. Convexal subarachnoid hemorrhage itself has been proposed as supportive of this theory. 18 The objectives of this multicentric study were therefore threefold. First, to better characterize the clinical spectrum and prognosis of CAA-related cSAH in the elderly. Second, to show its association with CAA in a neuroimaging, genetic, and cerebrospinal fluid (CSF) biomarker study. Third, to study its association with ICH and to find evidence of acute or chronic cortical ischemia associated with the cSAH, which would support the aforementioned theory.
MATERIALS AND METHODS

Study Participants and Data Collection
Ambispective observational study of a convenient cohort from five tertiary care hospitals in Barcelona, Spain. Patients were recruited between 2008 and 2013. Radiologic reports were reviewed to screen those with a potential cSAH.
We included patients over 60 years who met the Kumar description for cSAH, in which the bleeding localized in the convexities of the brain without involvement of the adjacent parenchyma or extension into the interhemispheric fissures, basal cisterns, or ventricles. 1 Medical records, laboratory data, and imaging studies were sent to the coordinating center for evaluation-(HSP (Hospital de la Santa Creu i Sant Pau))-where a centralized readout of the computed tomography (CT) or MRI images, blinded to clinical, genetic, and CSF data, was performed. Follow-up information was obtained by outpatient consultation or telephone interview.
We suggested the cSAH patients to undergo a formal cognitive evaluation, a lumbar puncture, and APOE genotyping. For biochemical studies, CSF samples from non-cSAH CAA patients (CAAo), AD patients, and healthy controls (HC) were used. For genetic studies, DNA samples from CAAo patients, AD patients, and HC were selected from the Memory Unit of HSP.
We reviewed CAA patients from our Memory Unit cohort with available echo gradient or susceptibility MRI images without cSAH to select CAAo patients. We selected patients who met the modified Boston criteria for probable CAA and with genetic and CSF data available. Twelve patients were identified. They all were assessed because of cognitive impairment. In addition, 6/12 had presented with focal neurologic symptoms (visual disturbances in 3, seizures in 2, and a frontal syndrome in 1). More information is provided in Supplementary Material.
Patient outcome at follow-up was graded following the modified Rankins Scale (mRS).
The ethics committee from Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) approved the study.
Cognitive Assessment
We suggested every cSAH patient to complete the study with a formal cognitive evaluation (Supplementary Table 1 ).
Neuroimaging Data
All cSAH patients underwent a brain CT at admission in the emergency room and an MRI sometime during the process. All MRI scans included fluid attenuated inversion recovery, T2, T2*-GRE, and diffusion-weighted images (DWI). Some of the patients had also an angiographic study.
We assessed the modified Boston criteria for possible or probable CAA 5 in every patient as well as other CAA-associated features. The systematic evaluation of the MRI scans is detailed in Supplementary Material.
Cerebrospinal Fluid Biomarkers and Genetics
In cSAH patients who consented to a lumbar puncture, core CSF (AD) biomarkers (Aß42, total-Tau-t-Tau-and phosphorylated Tau at threonine-181-p-Tau-) and Aß40 were determined. The CSF samples from 44 AD patients, 12 CAAo, and 20 HC were used for comparison.
APOE genotype was determined in cSAH patients who consented. Blood samples from 539 AD patients, 12 CAAo, and 324 HC selected from our Memory Unit were used for comparison.
Methods for CSF acquisition and biomarker measurement are detailed in Supplementary Material.
Neuropathologic Study
Postmortem neuropathologic brain examination of one patient was performed, according to standardized protocols. 19 
Statistical Methods
Statistical analyses were performed with the software Statistical Package for the Social Sciences v19 (http://www-01.ibm.com/software/es/analytics/ spss/). Allele frequencies (proportion of chromosomes in which the allele was present) were compared using 2 × 2 tables with Fisher's exact test for significance. To study the differences of CSF biomarker levels between groups, we used the Mann-Whitney U test. Statistical significance for all the analyses was set at 5% (α = 0.05).
RESULTS
Clinical Findings
Twenty-two patients with cSAH were included. Table 1 contains available data and Table 2 contains demographic data and neuroimaging findings.
The most frequent clinical presentation consisted of transient episodes of acute sensory and motor symptoms. In most cases they lasted less than 30 minutes. The episodes were usually repetitive and stereotyped (16 patients) and remitted completely. One patient died during admission because of an ICH 2 days after the cSAH.
Symptoms were related to cSAH topography, being negative ('stroke-like') in 6, positive in 4 ('prolonged aura-like'), and combined (positive and negative symptoms) in 12 patients. The most common positive symptoms were paresthesias (12 patients), affecting mouth and hand in all cases, and dysarthria (11 patients). Other less common symptoms included aphasia (5 patients), right cortical signs (2 patients), limb-jerking episodes (2 patients), and arm stiffness sensation (1 patient). None of our patients had thunderclap headache (2 presented nonspecific headache). One patient had a generalized tonicoclonic seizure. Surface electroencephalography was performed in 11 patients. Epileptiform activity was only found in 1 patient.
At least one vascular risk factor was present in all patients (77.3% had hypertension, 54.5% had dyslipidemia, and 18.2% had diabetes mellitus). Five patients had a history of heart attack, and six of them had a history of previous stroke (four with lobar hematomas, all of them symptomatic). Eleven patients were taking antithrombotic drugs at the time of cSAH (nine antiplatelets and two anticoagulant drugs, both in the normal range of international normalized ratios-between 2 and 3). The median follow-up (available in 21 patients) was 30.7 months (range 0.1 to 49.3 months). Follow-up information revealed 6 patients had an ICH, located at the site of the previous cSAH in four cases; 4 of these patients died soon after the ICH and 2 required nursing care. In every case, it was a symptomatic ICH that was diagnosed with a TC scan. No follow-up imaging was performed in clinically stable patients. Regarding functional dependence, 47.6% of the patients had a favorable outcome (mRS 0 to 2) and 52.4% were disabled (mRS ⩾ 3).
When focusing on the four patients with a previous ICH, 1 of them died, 3 remained functionally disabled (mRS: 4 to 5). The 3 survivals developed a dementia on the follow-up.
Neuropsychologic Features
Ten cSAH patients consented to a neuropsychologic assessment.
At the time of the cSAH, 6 patients had a diagnosis of mild cognitive impairment (MCI) and 2 of mixed dementia. During the follow-up, 6 previously unimpaired patients were diagnosed with MCI and 1 with dementia. Four further MCI patients progressed to dementia. From the 10 patients formally evaluated, 1 was cognitively spared, 8 had memory impairment (6 with involvement of additional cognitive domains), and 1 had only executive dysfunction (details in Supplementary Table 1 ). The neuropsychologic profile was heterogeneous as was the degree of cognitive impairment (CDR-SOB ranging from 0.5 to 12). In 4 of the 10, there were no reports of cognitive impairment before the cognitive evaluation.
Imaging Findings
Each patient had an MRI sometime during the process; 16/22 were performed in the acute phase before discharge (median time 4 days; range 0 to 11 days). MRI was deferred in three patients, specifically for this study (0.16, 0.63, and 2.40 years after the cSAH). Three patients had an MRI before the cSAH and had already been diagnosed with CAA-related ICH (3.5 years, 2 years, and 7 days before the cSAH).
Conventional angiography was performed in 3 patients, MR angiography in 10, CT angiography in 4, or both MR and CT in 1. The angiographic study was negative in all cases except in 2 patients who had an aneurysm affecting the contralateral vertebral artery and the posterior cerebral artery respectively, interpreted as incidental.
Neuroimaging data are summarized in Table 2 and Supplementary Table 2 . CT detected the acute cSAH in all but 1 subject, who was later diagnosed by MRI fluid attenuated inversion recovery images.
Modified Boston Criteria for Cerebral Amyloid Angiopathy and Systematic Evaluation of the Magnetic Resonance Imaging Thirteen patients met the diagnosis of possible CAA and nine probable CAA. Radiologic findings are shown in Table 2 .
Sixteen patients underwent an MRI during the acute phase before discharge that included DWI sequences. The DWI showed restricted diffusion involving the adjacent cortex surrounding the cSAH in 7 patients (Figure 1, Supplementary Figure 1) . Moreover, 2 patients had chronic cortical infarcts in the vicinity of cSS or cSAH.
Cerebrospinal Fluid Biomarkers and APOE Genotype
Cerebrospinal fluid was available in 7 cSAH patients. The median time between the vascular event and the lumbar puncture was 16 months (range 2 to 33 months). The results are shown in Figure 2 and Table 3 .
The CSF profile was similar in cSAH and CAAo patients. We found significant reductions in CSF Aβ42 and Aβ40 levels, elevations in CSF t-Tau, and a trend in p-Tau with respect to HC. The AD patients showed significantly higher levels of t-Tau and p-Tau than cSAH and CAAo patients but no differences in CSF Aß42 and Aß40.
APOE genotype determination was performed in 13 cSAH patients. The APOE genotypes are summarized in Table 3 . APOE-ε2 (allelic frequency of 19.2%) was significantly overrepresented in the cSAH group with respect to HC (5.4%; odds ratio 4.17). APOE-ε4 was significantly overrepresented in the CAAo group. There was no association of cSAH with APOE-ε4 genotype. The AD patients CAA-related atraumatic cSAH showed the expected underrepresentation of APOE-ε2 (3.4%) and overrepresentation of APOE-ε4 (25.5%) compared with HC.
Neuropathologic Study Pathologic brain examination was conducted in 1 cSAH patient. It showed neuropathologic changes associated with severe AD, severe amyloid angiopathy with capilar involvement, extense leptomeningeal siderosis, cortical microbleeds, and multiple intracortical microinfarcts (Figure 3 ) (Clinical and neuropathologic data are available in Supplementary Material).
DISCUSSION
To our knowledge, this is the first study evaluating genetic and CSF biomarkers in cSAH in elderly people. Our main findings were as follows. First, the clinical presentation in CAA-related cSAH was fairly homogenous and associated with poor prognosis because of its frequent association with ICH and cognitive impairment in the follow-up. Second, our CSF results, neuroimaging data, the association with APOE-ε2 and lobar ICH suggest that CAA is the underlying cause of cSAH in our patients, as confirmed by postmortem brain examination in one subject. And third, the evidence for acute cortical ischemia in the cortex adjacent to the cSAH could support the theory that ICH in some of these patients might originate in the subarachnoid space and progress through an ischemic cortex into the brain. The clinical presentation in our series was congruent with previous descriptions, consisted of transient focal neurologic symptoms related to the topography of the cSAH. 20 These symptoms were mostly recurrent, stereotyped, and brief. This transient presentation probably contributes to making cSAH an underdiagnosed entity. 2 There are discrepancies in the literature regarding the pathophysiology of the symptoms. Epileptic and •) ). P-valueso 0.05 are marked with a star (*) when compared with cSAH group. Main results for APOE-ε2 are cSAH versus AD (P = 0.002); cSAH versus HC (P = 0.01); cSAH versus CAAo (P = 0.192). Main results for APOE-ε4 are cSAH versus CAAo (P = 0.001); CAAo versus AD (P = 0.001); CAAo versus HC (Po0.001); and AD versus HC (Po 0.001).
CAA-related atraumatic cSAH migraine aura-like cortical spreading depression mechanisms have been proposed, but other mechanisms are possible. 15, 20 However, the lack of abnormal electroencephalography findings in our study and the finding of cSAH-related acute cortical ischemia-which has been associated with spreading depression in aneurysmatic SAH and stroke-broadly favor the nonepileptic mechanism. 21 Cerebral amyloid angiopathy can be associated with both MCI and full-blown dementia. 22, 23 The pattern of cognitive impairment is related to the underlying mechanisms (CAA-related ICH or infarcts, leukoaraiosis, Alzheimer-type pathology, or CAA by itself). 22 We were able to identify all these mechanisms in our patients, explaining both the very high prevalence and incidence of cognitive impairment and the different patterns and degrees observed. No imaging follow up was performed in non-(new) symptomatic patients. Although cSAH did not recur, the frequent occurrence of ICH and cognitive impairment explains the poor outcome in our patients. Therefore, while previous literature suggested that cSAH had a favorable prognosis the only study with a long follow-up reported a poor outcome in cSAH, specially in those patients with neuroimaging findings compatible with CAA. 2, 15, 24 Our neuroimaging, genetic, and CSF biomarker findings support the hypothesis that CAA is the underlying cause of cSAH in our patients. On MRI, 40.9% of patients fulfilled the modified Boston Criteria for probable CAA and 51.1% for possible CAA. Microbleeds and cSS might be related to different pathophysiologies. 25 We found a high frequency of disseminated cSS beyond the cSAH location, in agreement with previous studies in which transient focal neurologic episodes were the strongest clinical marker for cSS. 5, 26 These figures, however, greatly differ from epidemiologic studies of AD in which cSS is found in only 1% of cases. 27, 28 Microbleeds were found in 40%, in contrast to a prevalence of 68% in ICH series and 25% in AD series. 28, 29 These observations could be contextualized within the idea highlighted by Charidimou and Jäger, in which several different endophtenotypes of CAA may exist. Our patients would fit in the group of 'macrobleeders', where there is a low microbleed count and cSS would be associated itself with high risk of hemorrhage. 25, 30 The CSF profile in cSAH patients characterized by reductions in Aß40 and Aß42 is consistent with the profile reported in CAA. 7, 8 This pattern was previously found in two cSAH patients and in four cSS patients. 8, 9 The mild elevation in CSF t-Tau and p-Tau levels (significantly lower than in AD patients) is consistent with a lower level of tau-containing pathology in CAA. However, in the patient with neuropathologic study, extensive tau-positive neurofibrillary pathology was observed. We also found an overrepresentation of the APOE-ε2 allele in cSAH but not of APOE-ε4. Although there are no previous genetic studies in cSAH, APOE-ε2 and APOE-ε4 are independent risk factors for ICH. 12, 13 The fact that the CSF profile is similar in cSAH and CAAo patients indicates that there is an underlying CAA but also raises the possibility that mechanisms other than amyloid burden may have a role in cortical and leptomeningeal vessel fragilty leading to cSAH and cSS.
APOE-ε2 and APOE-ε4 might promote CAA-related hemorrhage through separate mechanisms: APOE-ε4 would enhance amyloid deposition, whereas APOE-ε2 would favor amyloid-laden vessels to undergo the vasculopathic changes that lead to rupture. 31 This hypothesis would explain the influence of APOE-ε2, but not of APOE-ε4 on ICH expansion. 12 The high association of cSAH with ICH in our series together with the observation of acute cortical ischemia in the vicinity of cSAH (which would enable the extension of the hematoma to the brain parenchyma) could be an in vivo evidence for the hypothesis of Takeda et al 16, 17 concerning CAA-related ICH pathogenesis. 32 Our results are also compatible with the 'tsunami hypothesis' to explain hematoma growth. According to this theory, the brain blood vessels surrounding the initial bleeding in APOE-ε2 carriers are more prone to bleeding themselves, and contribute to hematoma enlargement. 12, 33, 34 In our study, the ICH was located in the vicinity of a previous cSAH (four patients) or cSS (two patients), a colocalization that has also been found in cSS. 35 Therefore, cSS might be a marker of vessel fragilty. 26 In fact, cSS, particularly if disseminated, has also been associated with an increased risk of symptomatic lobar ICH. 26 The chronic cortical infarct found in the vicinity of cSS also supports Takeda's theory. Of note, focal laminar cortical lesions after aneurysmatic SAH in the absence of macroscopic vasospasm are more common than territorial infarcts. 36, 37 The present study has some limitations. First of all, we used a convenient sample. This could affect the generalizability of the findings because our sample might not be representative of the general population. All patients who presented with cSAH in the emergency room or in the clinics between 200 and 2013 were included, so our sample equates to a great extent of the elder population in Barcelona. Second, the sample sizes in the biomarker subgroups were small. However, significant differences were found in the CSF and in the genetic analyses. Third, although the mean follow-up was 2 years, some patients had a shorter follow-up. However, cSAH was clearly associated with poor prognosis. Fourth, regarding the areas of restricted diffusion in close proximity to cSAH, one concern is that they might not necessarily reflect acute microinfarction, but instead restricted diffusion due to the presence of acute blood products. 38 The DWI signal intensity changes should be interpreted in light of the T2 signal intensity changes, especially at the earliest time point, when both, hematoma and acute ischemia, are hyperintense on DWI images. At the acute stage, hematomas are hypointense on T2weighted images. 38 The fact that our cSAH was hyperintense on T2-weighted images suggests the presence of acute cortical ischemia in the vicinity of cSAH, more than restricted diffusion due to the presence of acute blood products. Furthermore, in some of the cases, chronic infarctions were found in the vicinity of SS both in the MRI and in the pathologic examination. On the other side, the association between cSAH or cSS and ischemic lesions might just indicate focally active severe CAA-related disease and the observation of cortical ischemia could be due to microvascular spasm, cerebral autoregulation impairment or other mechanisms. Those findings should be taken with caution and require further study to be confirmed. Finally, definite histologic CAA diagnosis, was only available in one patient.
In conclusion, our biomarker and genetic study supports an underlying CAA pathology for cSAH in elderly patients. Convexal subarachnoid hemorrhage might be considered a warning sign for poor prognosis because of its frequent association with cognitive impairment and ICH. The frequent lobar ICH in these patients might originate in the subarachnoid space and progress through an ischemic cortex into the brain. However, further studies with neuropathologic confirmation are needed to confirm these hypotheses.
